Digital Science delivers strategic intelligence across the biopharma R&D lifecycle, from emerging research trends and drug target discovery to KOL identification, clinical trial optimization, and IP analysis. Our platforms transform fragmented scientific, patent, and clinical data into actionable insights that accelerate breakthrough drug development.
Visit us at booth 710 to discover how our platforms power smarter, faster biopharma R&D. Don’t miss our session, “Building a Data Foundation for Trusted AI in Drug Target Identification and Repurposing,” where Stephen Leicht, President of Digital Science, will explore how knowledge graphs and generative AI unify complex data to drive more reliable, explainable drug discovery.
Meet our speaker
Steve Leicht
President, Digital Science
Steve serves as President and a Board Director of Digital Science Research Solutions Inc., alongside board roles for its international counterparts. His extensive career includes leadership positions at 52Inc and Collexis Holdings, where he drove substantial growth, fundraising, and market expansion. Steve’s background also encompasses general management at IBM and founding his own company, complemented by an MBA from The Pennsylvania State University’s Smeal College of Business.